- Home
- STTK vs OVID Comparison
STTK vs OVID Comparison
Compare STTK & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- OVID
- Stock Information
- Founded
- STTK 2016
- OVID 2014
- Country
- STTK United States
- OVID United States
- Employees
- STTK N/A
- OVID N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- OVID Health Care
- Exchange
- STTK Nasdaq
- OVID Nasdaq
- Market Cap
- STTK 56.8M
- OVID 54.1M
- IPO Year
- STTK 2020
- OVID 2017
- Fundamental
- Price
- STTK $1.11
- OVID $0.74
- Analyst Decision
- STTK Hold
- OVID Strong Buy
- Analyst Count
- STTK 3
- OVID 5
- Target Price
- STTK $2.00
- OVID $4.04
- AVG Volume (30 Days)
- STTK 172.1K
- OVID 384.9K
- Earning Date
- STTK 02-27-2025
- OVID 03-07-2025
- Dividend Yield
- STTK N/A
- OVID N/A
- EPS Growth
- STTK N/A
- OVID N/A
- EPS
- STTK N/A
- OVID N/A
- Revenue
- STTK $6,435,000.00
- OVID $631,695.00
- Revenue This Year
- STTK $313.04
- OVID $71.38
- Revenue Next Year
- STTK N/A
- OVID $5,144.81
- P/E Ratio
- STTK N/A
- OVID N/A
- Revenue Growth
- STTK 382.75
- OVID 113.21
- 52 Week Low
- STTK $0.94
- OVID $0.68
- 52 Week High
- STTK $11.76
- OVID $4.10
- Technical
- Relative Strength Index (RSI)
- STTK 44.36
- OVID 25.31
- Support Level
- STTK $1.13
- OVID $0.75
- Resistance Level
- STTK $1.22
- OVID $1.01
- Average True Range (ATR)
- STTK 0.11
- OVID 0.07
- MACD
- STTK -0.01
- OVID -0.02
- Stochastic Oscillator
- STTK 15.15
- OVID 6.25
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.